Volume : 10, Issue : 02, February – 2023

Title:

42.METHOD DEVELOPMENT AND VALIDATION OF UMECLIDINIUM AND VILANTEROL IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC
‬

Authors :

G. Anusha , S. K Godasu , D. Varun , Praveen Gujjula , Nimma vijayarekha

Abstract :

A new, simple, precise, rapid, selective and stability reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for the simultaneous quantification of Vilanterol and Umeclidinium in pure form and its pharmaceutical dosage form. The method is based on Agilent Zorbax XDB C18(150mm×4.6mm,5μ). The separation is achieved using isocratic elution by Potassium dihydrogen phosphate: Methanol (40:60) v/v, pumped at flow rate 1.0mL/min and UV detection at 235nm. The column is maintained at 25°C throughout the analysis. The total run time is about 6min. The method is validated for specificity, accuracy, precision and linearity, robustness and ruggedness, system suitability, limit of detection and limit of quantitation as per international conference of harmonization (ICH) Guidelines. The method is accurate and linear for quantification of Vilanterol, Umeclidinium between 50 – 150µg/mL and 50 – 150µg/mL respectively. Further, satisfactory results are also established in terms of mean percent- age recovery for Umeclidinium, intra-day and inter-day precision (<2%) and robustness. The advantages of this method are good resolution with sharper peaks and sufficient precision. The results indicate that the method is suitable for the routine quality control testing of marketed tablet formulations.
Keywords: Vilanterol and Umeclidinium, RP-HPLC, ICH Guidelines, Accuracy, Precision

Cite This Article:

Number of Downloads : 10

References:

1. Harrell AW, Siederer SK, Bal J, Patel NH, Young GC, Felgate CC, Pearce SJ, Roberts AD, Beaumont C, Emmons AJ, Pereira AI, Kempsford RD: Metabolism and disposition of vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89-100. doi: 10.1124/dmd.112.048603. Epub 2012 Oct 4.
2. Spyratos D, Sichletidis L: Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther Clin Risk Manag. 2015 Mar 25;11:481-7. doi: 10.2147/TCRM.S67491. eCollection 2015.
3. FDA Approved Drug Products: Breo Ellipta (fluticasone furoate/vilanterol) powder for inhalation
4. FDA Approved Drug Products: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) powder for inhalation (December 2022)
5. FDA Approved Drug Products: ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) for oral inhalation use
6. FDA Approved Drug Products: INCRUSE ELLIPTA (umeclidinium inhalation powder) for oral inhalation use.
7. Goudagatla Rajesh , K. Thejomoorthy and P. Sreenivasa Prasanna. New stability indicating high performance liquid chromatography method for determination of vilanterol and umeclidinium bromide in bulk and tablet dosage form. ejbps, 2021, Volume 8, Issue 6, 399-408.
8. Siva kishore masimukku, Rambabu chintala. Development and validation of spectrophotometric methods for simultaneous estimation of vilanterol and fluticasone furoate in pharmaceutical formulations. Asian Journal of pharmaceutical and clinical Research. Vol 10, Issue 4, 2017, 302-305.
9. A. Shammout, M. J., Yousef, H. . B., Abu-Shandi, K. H., Alomari, M. I., Hasan, M. R., Al-Othman, A. O., & Manasreh, W. A. (2021). Method Development And Validation Of The Chromatographic Analysis Of Fluticasone Propionate And Salmeterol Xinafoate Combination In Solutions And Human Plasma Using Hplc With Uv Detection. International Journal Of Applied Pharmaceutics, 13(4), 204–210.
10. Diviti Sai Sindhu, S. Shoba Rani. Stability indicating RP-HPLC method development and validation for the simultaneous estimation of vilanterol and umeclidinium bromide in bulk and pharmaceutical dosage forms. World J Pharm Sci 2022; 10(01): 128-135
11. Haritha Pavani et al, Stability Indicating Method Development And Validation For The Estimation Of Fluticasone Furoate And Vilanterol Trifenatate By RP-UPLC., Indo Am. J. P. Sci, 2021; 08(02).